Xbrane Biopharma Logo

Xbrane Biopharma

XBRANE | ST

Overview

Corporate Details

ISIN(s):
SE0007789409 (+1 more)
LEI:
5493008DKD05APTKQO39
Country:
Sweden
Address:
RETZIUS VÄG, 8, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Xbrane Biopharma is a biotechnology company specializing in the development of biosimilars, which are affordable, follow-on versions of approved biological drugs. The company's mission is to increase global access to treatments for serious diseases such as cancer, rheumatoid arthritis, and macular degeneration. Xbrane leverages a patented, high-yield production platform technology designed to significantly reduce manufacturing costs, aiming for up to an 80% cost reduction compared to standard systems. Its development portfolio includes biosimilar candidates targeting major biologic drug markets, such as Xlucane™ (a ranibizumab biosimilar) and BIIB801 (an adalimumab biosimilar).

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Xbrane Biopharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-31 21:00
Share Issue/Capital Change
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") har enligt tidigare offentliggjo…
Swedish 64.5 KB
2025-07-31 21:00
Share Issue/Capital Change
Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously ann…
English 64.3 KB
2025-07-16 12:24
Major Shareholding Notification
Swedish 10.1 KB
2025-07-11 08:30
Prospectus
Xbrane publishes disclosure document regarding admission to trading of the newl…
English 80.6 KB
2025-07-11 08:30
Share Issue/Capital Change
Xbrane offentliggör undantagsdokument avseende upptagande till handel av de nye…
Swedish 72.9 KB
2025-07-03 11:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
Swedish 62.1 KB
2025-07-03 11:00
Share Issue/Capital Change
Announcement from extra general meeting in Xbrane Biopharma AB
English 62.4 KB
2025-06-10 05:15
Pre-Annual General Meeting Information
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
Swedish 69.0 KB
2025-06-10 05:15
Pre-Annual General Meeting Information
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
English 70.2 KB
2025-06-10 05:00
Share Issue/Capital Change
Xbrane har, villkorat av godkännande av en extra bolagsstämma, beslutat att gen…
Swedish 98.9 KB
2025-06-10 05:00
Share Issue/Capital Change
Xbrane has, subject to the approval by an EGM, resolved to carry out an oversub…
English 99.5 KB
2025-06-09 17:31
Share Issue/Capital Change
Xbrane offentliggör avsikt att genomföra en riktad emission om cirka 200 MSEK
Swedish 87.8 KB
2025-06-09 17:31
Share Issue/Capital Change
Xbrane announces its intention to carry out a directed issue of shares of appro…
English 89.0 KB
2025-06-04 13:45
M&A Activity
Xbrane Biopharma slutför försäljning av XB003 och delar av sin organisation til…
Swedish 59.1 KB
2025-06-04 13:45
M&A Activity
Xbrane Biopharma Completes Sale of XB003 and Parts of Its Organization to Alvot…
English 58.8 KB

Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-09-07 Karl Martin Erik Åmark Other Buy 8,000 262,800.00 SEK
2023-09-07 Siavash Bashiri Other Sell 6,000 194,700.00 SEK
2023-09-07 Siavash Bashiri Other Buy 1,417 45,547.20 SEK
2023-09-06 Siavash Bashiri Other Sell 5,000 168,250.00 SEK
2023-09-06 Nina Ivers Other Other 4,000 896.80 SEK
2023-09-06 David Vikström Other Other 3,000 672.60 SEK
2023-09-06 David Vikström Other Other 3,000 N/A
2023-09-05 Karl Martin Erik Åmark Other Sell 8,000 272,400.00 SEK
2023-09-05 Maria Helene Edebrink Other Other 4,300 964.06 SEK
2023-09-05 Maria Helene Edebrink Other Other 3,000 672.60 SEK

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK